Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
285
-
Total 13F shares, excl. options
-
50.4M
-
Shares change
-
-1.35M
-
Total reported value, excl. options
-
$3.96B
-
Value change
-
-$106M
-
Put/Call ratio
-
2.99
-
Number of buys
-
139
-
Number of sells
-
-118
-
Price
-
$78.65
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q4 2022
316 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q4 2022.
HAEMONETICS CORP - Common Stock (HAE) has 285 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.4M shares
.
Largest 10 shareholders include Capital Research Global Investors (5.96M shares), BlackRock Inc. (5.87M shares), VANGUARD GROUP INC (5.24M shares), WELLINGTON MANAGEMENT GROUP LLP (4.03M shares), Neuberger Berman Group LLC (3.87M shares), STATE STREET CORP (1.69M shares), FRANKLIN RESOURCES INC (1.35M shares), FMR LLC (1.23M shares), Fisher Asset Management, LLC (1.11M shares), and SCHRODER INVESTMENT MANAGEMENT GROUP (953K shares).
This table shows the top 285 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.